Introduction: Commercially available prostaglandin analogues (PGAs) activate the
prostaglandin F receptor (FP) reducing intraocular pressure (IOP), thereby stabilizing …

Introduction Glaucoma is a leading cause of blindness with intraocular pressure (IOP) as the
only known modifiable risk factor. Prostaglandin FP receptor agonists are the first-line …

Introduction: Prostaglandin F2α analogs were the first prostaglandin agonists introduced for
glaucoma treatment. Thanks to their efficacy and favorable tolerability they set a high bar in …

Introduction In the last 25 years, topical prostaglandin analogues (PGAs) have emerged to
become first line and first choice therapeutic options in the management of glaucoma and …

Intraocular pressure reduction is the only available and evidence-based medical therapy for
glaucoma. Currently, the first-line eye drops are prostaglandin analogues including …

Prostaglandin F2α analogues are the most recent class of ocular hypotensive drugs that
have become available for clinical use in patients with glaucoma. The terms 'prostanoids' …

Glaucoma is a major cause of irreversible blindness worldwide. Reducing intraocular
pressure (IOP) is currently the only approach to prevent further optic nerve head damage …

Glaucoma is a disease process characterized by progressive optic nerve damage and
corresponding visual field loss. It may be further categorized into either primary open-angle …

Prostaglandin (PG) receptors represent important druggable targets due to the many diverse
actions of PGs in the body. From an ocular perspective, the discovery, development, and …

This introductory overview considers the advantages of a class of local hormones—the
prostaglandins (PGs)—for the management of intraocular pressure (IOP) in glaucoma, over …